Sign in
Active, not recruitingNo phase

Safety and Efficacy of the ANTHEM™ CR Total Knee System

Key facts

Who runs it
Smith & Nephew Pte Ltd
Where
India, Italy, South Africa, and South Korea8 sites in 4 countriesChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
153 people enrolled
Started
23 Nov 2018
Expected to end
1 Aug 2034
Type of study
Observational
Treatments tested
  • ANTHEM™ CR Total Knee System
Record updated
10 March 2026

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • Subject is a candidate for primary total knee arthroplasty due to degenerative joint disease
  • Subject is willing to sign and date an EC-approved consent form
  • Subject has posterior cruciate ligament and all collateral ligaments intact in the index joint
  • Subject is 18 to 75 years old at time of inclusion
  • Subject plans to be available through ten (10) years postoperative follow-up
  • Subject agrees to follow the study protocol
  • Subject has achieved skeletal maturity as deemed by enrolling investigator

Who cannot take part

  • Subject would receive the ANTHEM™ CR Total Knee System on the affected knee as a revision for a previously failed (TKA) or unicondylar knee arthroplasty (UKA)
  • Subject received TKA on the contralateral knee as a revision for a previously failed TKA or UKA
  • Subject has an active infection or sepsis (treated or untreated) or previous intra-articular infections
  • Subject has contralateral lower extremity condition causing abnormal ambulation (e.g. ankle fusion, ankle arthroplasty, previous hip fracture)
  • Subject has a history of patellar fracture, patellectomy, or patello-femoral Instability
  • Inadequate bone stock which would make the procedure unjustifiable including but not limited to: severe osteopenia/osteoporosis or family history of severe osteoporosis/osteopenia as deemed by the enrolling investigator
  • Subject has collateral ligament insufficiency
  • Subject has presence of malignant tumor, either primary or metastatic, or benign tumor on leg with the knee to be treated
  • Subject has an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study, including mental illness, mental retardation, drug or alcohol abuse
  • Subject has conditions that may interfere with the TKA survival or outcome (e.g. Paget's or Charcot's disease, vascular insufficiency, muscular atrophy, uncontrolled diabetes mellitus [i.e. not under treatment with oral/injectable medications to control blood glucose levels], fibromyalgia, moderate to severe renal insufficiency or neuromuscular disease)
  • Subject has inflammatory arthritis
  • Subject possesses a contralateral or ipsilateral revision hip arthroplasty
  • Subject has ipsilateral hip arthritis resulting in flexion contracture
  • Subject has one or more of the following arthroplasties that are not fully healed and well-functioning, as determined by the Investigator:; Ipsilateral or contralateral primary total hip arthroplasty or hip resurfacing arthroplasty; Contralateral primary TKA or UKA
  • Women who are pregnant, nursing, or of child-bearing potential who are not utilizing highly effective birth control measures
  • Participation in the treatment period of another clinical trial within thirty (30) days of Visit 1
  • Any subject that meets the definition of a Vulnerable Subject per ISO14155:2011: individual whose willingness to volunteer in a clinical investigation could be unduly influenced by the expectation, whether justified or not, of benefits associated with participation or of retaliatory response from senior members of a hierarchy in case of refusal to participate

This trial has no sites in United States.

It has sites in 4 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

This clinical study will evaluate the short-term (1- and 2-year) and medium term (5-year) safety and performance of the ANTHEM™ CR Total Knee System in patients with non-inflammatory degenerative joint disease of the knee requiring total knee replacement. Clinical, radiographic, Health Economic Outcomes and safety outcomes will be evaluated.

Treatments tested

  • ANTHEM™ CR Total Knee System

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective, Multicentre, Cohort Study Assessing the Safety and Efficacy of the ANTHEM™ CR Total Knee System in Patients Following a Total Knee Arthroplasty
Record updated
10 March 2026